The benefit of omega-3’s in cardiovascular disease prevention may be as important as the drugs that control cholesterol.
Polyunsaturated fatty acids from oily fish prevents cardiovascular events, which are the leading cause of mortality worldwide. Its use is recommended especially for patients with heart disease, but also to the general population. The blue fish meat is not only rich in omega 3, but has many more benefits.
Regular consumption of polyunsaturated fatty acids, especially omega 3, is suitable for individuals with cardiovascular risk and for the general population. Fish is a food rich in this nutrient. Even a recent study has found that its value “exceeds that of a nutritional supplement food base to set itself up.” Its benefit in terms of cardiovascular prevention, is considered as important as the statin drugs that reduce cholesterol levels.
The study’s lead author, Carl J. Lavie, at Ochsner Medical Center (New Orleans, USA), investigated in healthy people and survivors of myocardial infarction, patients with heart failure, atherosclerosis or atrial fibrillation. The results of monitoring, which lasted 30 years, have been published in the Journal of the American College of Cardiology.
Culture of omega 3
Consumption of polyunsaturated fatty acids not only benefits individuals with cardiovascular risk, but the entire population.
Lavie regrets that many physicians assume that the fish oil fatty acids, especially omega-3 health benefits, without stopping to inquire by what means, how and to what extent. Censorship that many physicians are aware of the tests carried out with statins, but are unaware of recent publications related to omega 3. In heart failure and patients who have suffered a heart attack, it has proven to prevent deaths and hospitalizations.
It is estimated that these groups should take oily fish in meals, at least four or five times a week.
The most studied are omega-3 docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA). The clinical benefits of these fatty acids have been shown in a total of four trials conducted with 40,000 patients, with and without cardiovascular disease.
